First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?
作者信息
van der Meulen Matthijs, Mason Warren P
机构信息
Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands.
出版信息
Neurooncol Pract. 2022 Mar 17;9(3):163-164. doi: 10.1093/nop/npac023. eCollection 2022 May.
Abstract
摘要
相似文献
1
First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?少突胶质细胞瘤（世界卫生组织3级）的一线化疗方案：PCV方案还是替莫唑胺？
Neurooncol Pract. 2022 Mar 17;9(3):163-164. doi: 10.1093/nop/npac023. eCollection 2022 May.
2
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.对于1p19q共缺失的间变性少突胶质细胞瘤患者，采用放疗联合替莫唑胺或PCV治疗。
Rev Neurol. 2018 Oct 16;67(8):293-297.
3
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.单纯 PCV 化疗治疗 WHO 分级 2 级少突胶质细胞瘤：疾病控制时间延长，恶性进展风险低。
J Neurooncol. 2021 Jun;153(2):283-291. doi: 10.1007/s11060-021-03765-z. Epub 2021 May 1.
4
Chemotherapy for the treatment of oligodendroglial tumors.用于治疗少突胶质细胞瘤的化疗
Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8. doi: 10.1016/s0093-7754(01)90066-1.
5
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.替莫唑胺用于PCV（丙卡巴肼、洛莫司汀和长春新碱）化疗后复发性少突胶质细胞瘤的二线化疗：欧洲癌症研究与治疗组织脑肿瘤组II期研究26972
Ann Oncol. 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157.
6
Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.神经肿瘤学临床辩论：PCV方案或替莫唑胺联合放疗用于新诊断的高级别少突胶质细胞瘤
Neurooncol Pract. 2019 Jan;6(1):17-21. doi: 10.1093/nop/npy044. Epub 2018 Nov 3.
7
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.少突胶质细胞瘤中的1p/19q缺失可预测对一线替莫唑胺的反应，但对挽救性治疗无预测作用。
Eur J Cancer. 2006 Oct;42(15):2499-503. doi: 10.1016/j.ejca.2006.05.021. Epub 2006 Aug 17.
8
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.新诊断的 1p/19q 共缺失的 2 级或 3 级胶质瘤患者的功能结局改善 - IMPROVE CODEL：NOA-18 试验。
BMC Cancer. 2022 Jun 13;22(1):645. doi: 10.1186/s12885-022-09720-z.
9
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.间变性少突胶质细胞瘤：一种新的治疗模式和当前的争议。
Curr Treat Options Oncol. 2013 Dec;14(4):505-13. doi: 10.1007/s11864-013-0251-7.
10
Grade II and III Oligodendroglioma and Astrocytoma.二级和三级少突胶质细胞瘤和星形细胞瘤。
Neurol Clin. 2018 Aug;36(3):467-484. doi: 10.1016/j.ncl.2018.04.005. Epub 2018 Jun 15.
引用本文的文献
1
Performance Comparison of Diffusion Kurtosis Imaging (DKI), Neurite Orientation Dispersion and Density Imaging (NODDI), and Diffusion Microstructure Imaging (DMI) in Predicting Adult-Type Glioma Subtype-A Pilot Study.扩散峰度成像（DKI）、神经突方向离散度与密度成像（NODDI）及扩散微结构成像（DMI）在预测成人型胶质瘤亚型中的性能比较——一项初步研究
Cancers (Basel). 2025 Mar 3;17(5):876. doi: 10.3390/cancers17050876.
2
Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas.多池化学交换饱和转移（CEST）及基于CEST的pH评估作为胶质瘤分级、异柠檬酸脱氢酶（IDH）突变、1p/19q共缺失和胶质瘤中O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的预测工具。
Front Oncol. 2024 Dec 20;14:1507335. doi: 10.3389/fonc.2024.1507335. eCollection 2024.
3
Glioma Type Prediction with Dynamic Contrast-Enhanced MR Imaging and Diffusion Kurtosis Imaging-A Standardized Multicenter Study.基于动态对比增强磁共振成像和扩散峰度成像的胶质瘤类型预测——一项标准化多中心研究
Cancers (Basel). 2024 Jul 25;16(15):2644. doi: 10.3390/cancers16152644.
4
Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy.医用气体等离子体技术：癌症治疗与免疫疗法路线图。
Redox Biol. 2023 Sep;65:102798. doi: 10.1016/j.redox.2023.102798. Epub 2023 Jun 27.
本文引用的文献
1
Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.替莫唑胺或PCV化疗用于1p/19q共缺失的世界卫生组织3级少突胶质细胞瘤的短期疗效：一项全国性评估。
Neurooncol Pract. 2022 Jan 14;9(3):201-207. doi: 10.1093/nop/npac004. eCollection 2022 May.
2
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.成人弥漫性星形细胞瘤和少突胶质细胞瘤的治疗：美国临床肿瘤学会-神经肿瘤学会指南
J Clin Oncol. 2022 Feb 1;40(4):403-426. doi: 10.1200/JCO.21.02036. Epub 2021 Dec 13.
3
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.美国 2014-2018 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. doi: 10.1093/neuonc/noab200.
4
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.EANO 成人弥漫性胶质瘤诊断与治疗指南。
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
5
Longitudinal molecular trajectories of diffuse glioma in adults.成人弥漫性神经胶质瘤的纵向分子轨迹。
Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.
6
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.新诊断的纯性和混合性间变性少突胶质细胞瘤患者使用高剂量替莫唑胺的疗效及患者报告的结局：一项II期多中心研究
J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.
7
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.国际回顾性研究纳入了超过 1000 例成人弥漫性少突胶质细胞瘤患者。
Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.
8
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.NOA-04 间变性胶质瘤序贯放化疗（采用丙卡巴肼、洛莫司汀和长春新碱或替莫唑胺）的随机 III 期试验
J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9.
9
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.替莫唑胺治疗新诊断的间变性少突胶质细胞瘤：一项临床疗效试验。
J Neurooncol. 2006 Sep;79(2):153-7. doi: 10.1007/s11060-005-9020-1. Epub 2006 Jul 20.
10
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.辅助性丙卡巴肼、洛莫司汀和长春新碱可改善新诊断的间变性少突胶质细胞瘤和少突星形细胞瘤的无进展生存期，但不能改善总生存期：一项欧洲癌症研究与治疗组织的随机 III 期试验。
J Clin Oncol. 2006 Jun 20;24(18):2715-22. doi: 10.1200/JCO.2005.04.6078.
Zotero 插件